Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Ann Oncol
; 28(10): 2429-2435, 2017 Oct 01.
Article
in En
| MEDLINE
| ID: mdl-28961832
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Proto-Oncogene Proteins p21(ras)
/
Deoxycytidine
Type of study:
Clinical_trials
/
Guideline
Aspects:
Patient_preference
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2017
Document type:
Article